MBI-002

Drug Profile

MBI-002

Alternative Names: MBI 002

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Mycenax Biotech
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Antigen presenting cell stimulants; Checkpoint kinase stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 May 2017 Preclinical trials in Solid tumours in Taiwan prior to May 2017 (unspecified route)
  • 15 May 2017 Mycenax announces intention to submit IND to US FDA for Solid tumours in 2019
  • 15 May 2017 An unknown EU Biotech company grants an exclusive worldwide license to Mycenax for the development of MBI-002 in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top